Oral Valganciclovir Versus Valacyclovir

Completed · Phase 2

Conditions studied: Chronic Lymphocytic Leukemia, Leukemia

In brief

To determine if the rate of cytomegalovirus reactivation during treatment with alemtuzumab (Campath) is reduced by the use of valganciclovir prophylaxis.

Key facts

Study ID

NCT00562770

Run by

M.D. Anderson Cancer Center

People needed

46

Starts

2003-09-01

Expected to finish

2006-07-01

Last updated by the study team

2012-07-31

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients receiving alemtuzumab
• Age > 15
• Signed informed consent form

You may not qualify if…

• Active cytomegalovirus disease or infection. Asymptomatic patients with positive CMV pp65 antigenemia will not be excluded.
• Patients with a creatinine clearance of < 10 ml/min as calculated via the Cockcroft-Gault equation.

Where it is running

• The University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.